

AMENDMENTS**Amendments to the Claims**

1. (Currently amended) A method for treating a skin disorder in a patient in need thereof, the method comprising the step of administering a therapeutically effective amount of a ~~reconstituted liquid solution of comprising a~~ botulinum toxin to a location of a skin disorder of the patient, wherein the administration of the botulinum toxin reduces at least one symptom of the skin disorder, thereby treating the skin disorder;
wherein the solution is administered by intradermal injection or subdermal injection; and
wherein the skin disorder comprises a disorder selected from the group consisting of wart[[s]], corns, a callus[[es]], a swelling or scarring of a nerve that connects two toes, hammertoes and, or a bunions, thereby treating the skin disorder.
2. (Currently amended) The method of claim 1, wherein the botulinum toxin is ~~selected from the group consisting of~~ a botulinum toxin type[[s]] A, a botulinum toxin type B, a botulinum toxin type C1, a botulinum toxin type D, a botulinum toxin type E, a botulinum toxin type F and, or a botulinum toxin type G.
3. (Original) The method of claim 1, wherein the botulinum toxin is a botulinum toxin type A.
4. (Original) The method of claim 1, wherein the botulinum toxin is administered in an amount of between about 1 unit and about 3,000 units.
5. (Currently amended) The method of claim 1, wherein the ~~administration is by topical or subcutaneous administration of the botulinum toxin~~ subdermal injection is a subcutaneous injection or an intramuscular injection.
6. (Currently amended) [[A]] The method of claim 1, wherein the wart is a common wart, a plantar wart or a flat wart for treating a skin disorder in a patient in need thereof, the

~~method comprising the step of locally administering between 1 unit and 3000 units of a reconstituted liquid solution of botulinum toxin to a skin disorder of the patient, wherein the skin disorder comprises a disorder selected from the group consisting of warts, corns, calluses, neuromas a swelling or scarring of a nerve that connects two toes, hammertoes and bunions, thereby treating the skin disorder.~~

7. (Cancelled)
8. (Currently amended) The method of ~~claim 6~~ claim 1, wherein the skin disorder is treated by reducing a pain associated with the skin disorder.
9. (Currently amended) The method of ~~claim 6~~ claim 1, wherein the skin disorder is treated by reducing inflammation associated with the skin disorder.
10. (Currently amended) The method of ~~claim 6~~ claim 1, wherein the skin disorder is treated by reducing the size of the skin disorder.
11. (Cancelled)
12. (Currently amended) A method for treating skin disorder in a patient in need thereof, the method comprising a step of administering a therapeutically effective amount of a ~~reconstituted liquid solution of comprising a~~ botulinum toxin to a location of a skin disorder of the patient, wherein the administration of the botulinum toxin reduces at least one symptom of the skin disorder, thereby treating the skin disorder;
wherein the solution is administered by intradermal injection or subdermal injection; and
wherein the skin disorder comprises a ~~disorder selected from the group consisting of~~ dermatofibroma, a mole, a granuloma and or a keratose, thereby treating the skin disorder.

13. (Currently amended) [[A]] The method of claim 12, wherein the botulinum toxin is a botulinum toxin type A, a botulinum toxin type B, a botulinum toxin type C1, a botulinum toxin type D, a botulinum toxin type E, a botulinum toxin type F, or a botulinum toxin type G. ~~method for treating a skin disorder in a patient in need thereof, the method comprising the step of administering a therapeutically effective amount of a reconstituted liquid solution of botulinum toxin via syringe to a location of a skin disorder of the patient, wherein the skin disorder comprises a disorder selected from the group consisting of warts, corns, calluses, a swelling or scarring of a nerve that connects two toes, hammertoes and bunions, thereby treating the skin disorder.~~
14. (Currently amended) The method of ~~claim 13~~ claim 12, wherein the botulinum toxin is selected from the group consisting of a botulinum toxin type[[s]] A, B, C, D, E, F and G.
15. (Currently amended) The method of ~~claim 13~~ claim 12, wherein the botulinum toxin is administered in an amount of between about 1 unit and about 3,000 units.
16. (Currently amended) The method of ~~claim 13~~ claim 12, wherein the skin disorder is treated by reducing a pain associated with the skin disorder.
17. (New) The method of claim 1, wherein the callus is a corn.
18. (New) The method of claim 17, wherein the corn develops due to a hammertoe.
19. (New) The method of claim 12, wherein the subdermal injection is a subcutaneous injection or an intramuscular injection.
20. (New) The method of claim 12, wherein the skin disorder is treated by reducing inflammation associated with the skin disorder.
21. (New) The method of claim 12, wherein the skin disorder is treated by reducing the size of the skin disorder.

22. (New) The method of claim 12, wherein the mole is a typical mole or a dysplastic mole.

23. (New) The method of claim 12, wherein the granulation is a pyogenic granuloma.

24. (New) The method of claim 12, wherein the keratose is a seborrheic keratose.

25. (New) A method for treating a skin disorder in a patient in need thereof, the method comprising the step of topically administering a therapeutically effective amount of a composition comprising a botulinum toxin to a location of a skin disorder of the patient, wherein the administration of the botulinum toxin reduces at least one symptom of the skin disorder, thereby treating the skin disorder;

wherein the composition is a cream or a lotion; and

wherein the skin disorder comprises a wart, a callus, a swelling or scarring of a nerve that connects two toes, a bunion, dermatofibroma, a mole, a granuloma, or a keratose.

26. (New) The method of claim 25, wherein the botulinum toxin is a botulinum toxin type A, a botulinum toxin type B, a botulinum toxin type C1, a botulinum toxin type D, a botulinum toxin type E, a botulinum toxin type F, or a botulinum toxin type G.

27. (New) The method of claim 25, wherein the botulinum toxin is a botulinum toxin type A.